Adding brentuximab vedotin to chemotherapy in pediatric Hodgkin lymphoma produced results that have been hailed as a paradigm shift and have just led to FDA approval for this new indication.
The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results. The findings, published in The New England Journal of Medicine, additionally showed the brentuximab vedotin (Adcetris, Seagen) regimen to be well tolerated.